Sickle Cell Disease: Improving the Quality and Continuum of Acute and Ambulatory Patient Care

Released On
February 7, 2022

Expires On
February 7, 2023

Media Type

Completion Time
90 minutes

Cardiology, Hematology-Oncology, Neurology, Pulmonology, Primary Care

Bleeding Disorders, Pain

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grants from Agios Pharmaceuticals, Chiesi USA, and Vertex Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward hematologists, cardiologists, pulmonologists, neurologists, primary care physicians, and advanced care providers who work with patients with sickle cell disease.

Program Overview

This online, on-demand virtual symposium brings together renowned experts in sickle cell disease (SCD). SCD is responsible for serious, life-threatening complications of hemolytic anemia, inflammation, impaired immunity to encapsulated organisms, and vascular occlusion. Secondary complications include stroke, acute and chronic organ damage, and a shortened life span. In the United States, there are more than 230,000 hospital admissions related to SCD annually. Despite the prevalence of SCD in patients and the experience treating them in the United States, there are still significant gaps and dissatisfaction in care.

The management of pain in individuals with SCD remains a significant clinical challenge, in part due to its complex and poorly understood pathophysiology. Pain associated with SCD can manifest as intermittent acute pain, daily chronic pain, and acute-on-chronic pain. There are features unique to SCD that create diagnostic challenges for providers in the emergency department and/or mask serious complications in patients, such as acute chest syndrome.

This educational activity is an archive of the live virtual symposium held on December 2, 2021.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify key features of acute vaso-occlusive pain in patients with SCD
  • Describe the associated complications from SCD-related acute pain episodes
  • Implement guideline-directed care plans for patients with SCD-related acute pain or complications
  • Integrate optimal strategies for the prevention and treatment of vaso-occlusive crises and chronic pain



Ifeyinwa Osunkwo, MD, MPH

Director, Sickle Cell Disease Enterprise
Professor of Medicine and Pediatrics
Levine Cancer Institute, Atrium Health
Charlotte, NC


Biree Andemariam, MD

Professor of Medicine
Division of Hematology/Oncology
Director, New England Sickle Cell Institute
Director, Connecticut Bleeding Disorders Center
University of Connecticut Health
Farmington, CT


Bernard L. Lopez, MD, MS, CPE

Associate Provost for Diversity and Inclusion
Thomas Jefferson University
Senior Associate Dean for Diversity and Community Engagement
Professor and Executive Vice Chair Department of Emergency Medicine
Sidney Kimmel Medical College of Thomas Jefferson University
Philadelphia, PA

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Ifeyinwa Osunkwo, MD, MPH
  • Grant/Research Support: PCORI, NC DPH and CDC; DSMB
  • Consultant: Novartis, GBT, Cyclerion, Takeda, Cheisi, Agios and FORMA Therapeutics, HCP Live
  • Speaker's Bureau: Novartis, Emmaus and GBT
  • Advisory board: Novartis, GBT, Acceleron, Cyclerion, Cheisi, Novo-Nordisc, Emmaus and FORMA Therapeutics
  • Other Support (please specify): DSMB membership for Micella Biopharma; Editor-In Chief for Hematology News
Biree Andemariam, MD
  • Grant/Research Support: Global Blood Therapeutics, Forma Therapeutics, Hemanext, Imara, Novartis
  • Consultant: Agios, Aruvant, bluebird bio, CRISPR/Vertex, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, NovoNordisk, Sanofi Genzyme, Terumo BCT

Bernard L. Lopez, MD, MS, CPE, has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.